LENZ Therapeutics (LENZ) and Its Competitors Critical Analysis

LENZ Therapeutics (NASDAQ:LENZ) is one of 290 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare LENZ Therapeutics to similar businesses based on the strength of its valuation, profitability, dividends, risk, earnings, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and target prices for LENZ Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	0	0	5	0	3.00
LENZ Therapeutics Competitors	1438	4559	11932	208	2.60

LENZ Therapeutics currently has a consensus price target of $31.33, suggesting a potential upside of 90.36%. As a group, “Biological products, except diagnostic” companies have a potential upside of 66.86%. Given LENZ Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe LENZ Therapeutics is more favorable than its rivals.

Institutional and Insider Ownership

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 38.4% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 16.2% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares LENZ Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-33.12%	-27.96%
LENZ Therapeutics Competitors	-4,480.02%	-224.14%	-45.19%

Earnings and Valuation

This table compares LENZ Therapeutics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
LENZ Therapeutics	N/A	-$124.65 million	-1.05
LENZ Therapeutics Competitors	$543.49 million	-$37.27 million	8.82

LENZ Therapeutics’ rivals have higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

LENZ Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, LENZ Therapeutics’ rivals have a beta of 1.10, indicating that their average share price is 10% more volatile than the S&P 500.

Summary

LENZ Therapeutics beats its rivals on 8 of the 13 factors compared.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.